These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19519556)

  • 1. Vasoproliferation and antiproliferative treatment options in pulmonary arterial hypertension.
    Blaukovitsch M; Zabel P; Hauber HP
    Recent Pat Cardiovasc Drug Discov; 2009 Jun; 4(2):142-9. PubMed ID: 19519556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human.
    Morales-Cano D; Barreira B; Callejo M; Olivencia MA; Ferruelo A; Milara J; Lorente JÁ; Moreno L; Cogolludo Á; Perez-Vizcaino F
    Vascul Pharmacol; 2024 Jun; 155():107371. PubMed ID: 38599357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia- or PDGF-BB-dependent paxillin tyrosine phosphorylation in pulmonary hypertension is reversed by HIF-1α depletion or imatinib treatment.
    Veith C; Zakrzewicz D; Dahal BK; Bálint Z; Murmann K; Wygrecka M; Seeger W; Schermuly RT; Weissmann N; Kwapiszewska G
    Thromb Haemost; 2014 Dec; 112(6):1288-303. PubMed ID: 25231004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension.
    Humbert M; Montani D; Perros F; Dorfmüller P; Adnot S; Eddahibi S
    Vascul Pharmacol; 2008; 49(4-6):113-8. PubMed ID: 18606248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydrogen ameliorates pulmonary hypertension in rats by anti-inflammatory and antioxidant effects.
    Kishimoto Y; Kato T; Ito M; Azuma Y; Fukasawa Y; Ohno K; Kojima S
    J Thorac Cardiovasc Surg; 2015 Sep; 150(3):645-54.e3. PubMed ID: 26095621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.
    Perros F; Ranchoux B; Izikki M; Bentebbal S; Happé C; Antigny F; Jourdon P; Dorfmüller P; Lecerf F; Fadel E; Simonneau G; Humbert M; Bogaard HJ; Eddahibi S
    J Am Coll Cardiol; 2015 Feb; 65(7):668-80. PubMed ID: 25677428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apple polyphenol relieves hypoxia-induced pulmonary arterial hypertension via pulmonary endothelium protection and smooth muscle relaxation: In vivo and in vitro studies.
    Hua C; Zhao J; Wang H; Chen F; Meng H; Chen L; Zhang Q; Yan J; Yuan L
    Biomed Pharmacother; 2018 Nov; 107():937-944. PubMed ID: 30257406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular Cyclophilin A, Especially Acetylated, Causes Pulmonary Hypertension by Stimulating Endothelial Apoptosis, Redox Stress, and Inflammation.
    Xue C; Sowden M; Berk BC
    Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1138-1146. PubMed ID: 28450293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats.
    Abe K; Shimokawa H; Morikawa K; Uwatoku T; Oi K; Matsumoto Y; Hattori T; Nakashima Y; Kaibuchi K; Sueishi K; Takeshit A
    Circ Res; 2004 Feb; 94(3):385-93. PubMed ID: 14670839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory signaling in pulmonary arterial hypertension: the controversial role of CRP, and the search for new therapies.
    Maciocia PM
    Cardiovasc Ther; 2010; 28(1):1-4. PubMed ID: 20074252
    [No Abstract]   [Full Text] [Related]  

  • 11. Adenosine A₂B receptor agonism inhibits neointimal lesion development after arterial injury in apolipoprotein E-deficient mice.
    Bot I; de Vries H; Korporaal SJ; Foks AC; Bot M; van Veldhoven J; Ter Borg MN; van Santbrink PJ; van Berkel TJ; Kuiper J; Ijzerman AP
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2197-205. PubMed ID: 22743060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative assessment of transient exposure of paclitaxel or zotarolimus on in vitro vascular cell death, proliferation, migration, and proinflammatory biomarker expression.
    Steinfeld DS; Liu AP; Hsu SH; Chan YF; Stankus JJ; Pacetti SD; Tai JT
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):179-86. PubMed ID: 22561362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice.
    Shimizu T; Fukumoto Y; Tanaka S; Satoh K; Ikeda S; Shimokawa H
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2780-91. PubMed ID: 24135024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAR-2 inhibition reverses experimental pulmonary hypertension.
    Kwapiszewska G; Markart P; Dahal BK; Kojonazarov B; Marsh LM; Schermuly RT; Taube C; Meinhardt A; Ghofrani HA; Steinhoff M; Seeger W; Preissner KT; Olschewski A; Weissmann N; Wygrecka M
    Circ Res; 2012 Apr; 110(9):1179-91. PubMed ID: 22461388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnesium attenuates endothelin-1-induced vasoreactivity and enhances vasodilatation in mouse pulmonary arteries: Modulation by chronic hypoxic pulmonary hypertension.
    Mu YP; Huang QH; Zhu JL; Zheng SY; Yan FR; Zhuang XL; Sham JSK; Lin MJ
    Exp Physiol; 2018 Apr; 103(4):604-616. PubMed ID: 29363240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostanoid EP₂ Receptors Are Up-Regulated in Human Pulmonary Arterial Hypertension: A Key Anti-Proliferative Target for Treprostinil in Smooth Muscle Cells.
    Patel JA; Shen L; Hall SM; Benyahia C; Norel X; McAnulty RJ; Moledina S; Silverstein AM; Whittle BJ; Clapp LH
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30103548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension.
    Chaumais MC; Guignabert C; Savale L; Jaïs X; Boucly A; Montani D; Simonneau G; Humbert M; Sitbon O
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):13-26. PubMed ID: 25421754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354.
    Hosokawa S; Haraguchi G; Sasaki A; Arai H; Muto S; Itai A; Doi S; Mizutani S; Isobe M
    Cardiovasc Res; 2013 Jul; 99(1):35-43. PubMed ID: 23631839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapies for the treatment of pulmonary hypertension.
    Stenmark KR; Rabinovitch M
    Pediatr Crit Care Med; 2010 Mar; 11(2 Suppl):S85-90. PubMed ID: 20216170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathology and pathobiology of pulmonary hypertension.
    Guignabert C; Dorfmuller P
    Semin Respir Crit Care Med; 2013 Oct; 34(5):551-9. PubMed ID: 24037624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.